| Serial Number | 79377424 |
| Word Mark | BIOXPEDIA |
| Filing Date | Tuesday, May 30, 2023 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Thursday, October 24, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 26, 2024 |
| Goods and Services | Provision of business statistical information relating to medical matters; compilation of statistical data relating to medical research for business purposes; compilation of statistics for business purposes; business assistance, management and administrative services; compilation of medical reports for business purposes |
| Goods and Services | Human healthcare services; medical laboratory analysis services relating to the treatment of persons; medical laboratory services for the analysis of samples taken from patients; medical laboratory services for the analysis of blood samples taken from patients; medical analysis services relating to the treatment of persons provided by a medical laboratory; medical services; medical screening; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical consultations; medical information; medical diagnostic services; medical counseling; providing medical information; issuing of medical reports; genetic testing for medical purposes; medical and health services relating to dna, genetics and genetic testing; medical analysis services for the diagnosis of cancer; DNA screening for medical purposes; RNA and DNA analysis for cancer diagnosis and prognosis for medical purposes; analysis of human serum for medical treatment; medical testing of urine; analysis of human tissues for medical treatment; medical treatment using cultured cells; cultured cell bank services for medical transplantation |
| Goods and Services | Analytical laboratory services, namely, laboratory research services in the field of biomarker discovery and validation for drug development; scientific and technological services, namely, providing assays and analytical methods for clinical research, drug discovery, and development; research relating to molecular sciences, specifically research involving molecular diagnostics, genomics, and proteomics for personalized medicine; genetic research specifically human genetic research focusing on gene expression profiling, genome-wide association studies, and genetic biomarker discovery; biological analysis; medical and pharmacological research services; biology consultancy; biological research; biological development services specifically development and optimization of biological assays and protocols for preclinical and clinical trials; biochemistry research services; laboratory services specifically for the analysis of proteins, nucleic acids, and small molecules using mass spectrometry, qPCR, ELISA; laboratory services, specifically for the analysis of proteins, nucleic acids, and small molecules using mass spectrometry, qPCR, dPCR, ELISA; biomedical research services; structural and functional analysis of genomes; natural science services, namely, natural science services, namely, scientific research in the fields of biochemistry, molecular biology, and pharmacology; medical research; medical research laboratory services; research in the field of gene therapy, including vector development, gene editing, and delivery mechanisms for therapeutic purposes; scientific research in the field of genetics; laboratory research in the field of gene expression; research in the field of gene editing technology, particularly using CRISPR-Cas9 and other gene-editing tools for therapeutic applications and functional genomics studies; scientific research for medical purposes in the area of cancerous diseases; dna conducting of scientific feasibility studies; DNA screening for scientific research purposes; DNA analysis to determine paternity; research and development services in the field of gene expression systems; analysis of human serum for medical research; analysis of human tissues for medical research; scientific research relating to the isolation and cultivation of human tissues and cells; cell culture services for scientific and research purposes, for others; toxicity analysis, namely, in vitro and in vivo toxicity testing of pharmaceuticals and chemical compounds for safety and efficacy assessments; toxicity testing for scientific research purposes; testing of pharmaceuticals for scientific research; blood analysis services for scientific research purposes |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 1, 2023 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 1, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, September 1, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | BioXpedia A/S |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | DK |
| Event Date | Event Description |
| Thursday, August 31, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, September 1, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, September 5, 2023 | APPLICATION FILING RECEIPT MAILED |
| Saturday, November 25, 2023 | NEW REPRESENTATIVE AT IB RECEIVED |
| Thursday, February 22, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, February 27, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, February 28, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, March 19, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, March 19, 2024 | REFUSAL PROCESSED BY MPU |
| Monday, April 8, 2024 | REFUSAL PROCESSED BY IB |
| Wednesday, September 18, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, September 18, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, September 18, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, October 18, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |